Pair page
Argireline with Pentapeptide-18
Mechanism-tag overlap and published literature for Argireline and Pentapeptide-18, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
snap-25-mimetic
cosmetic-peptide
enkephalin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Argireline and Pentapeptide-18 have published these mechanism-level observations. Not a co-administration recommendation.
An enkephalin-analogue pentapeptide that modulates the presynaptic delta-opioid receptor to reduce calcium-channel opening, decreasing acetylcholine release upstream of the SNARE complex. Frequently combined with Argireline in a "dual-mechanism neurotransmitter inhibition" stack. The Lipotec-sponsored original study suggested synergy, though independent replication is limited.
The flagship Lipotec pairing. Argireline is a SNARE-complex-interfering postsynaptic peptide (it competes with the N-terminus of SNAP-25 to destabilize vesicle fusion). Pentapeptide-18 is a presynaptic enkephalin-receptor agonist that reduces the calcium-triggered vesicle fusion signal itself. Combining them hits both sides of the neuromuscular junction in principle. The Lipotec 2005 internal study and the Dragomirescu 2014 open-label paper both report the 5% + 5% combination outperforming either peptide alone by roughly 2×. The combination is the standard-of-reference for high-tier topical "Botox alternative" serums.
Quick facts
Argireline
Pentapeptide-18
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Argireline | Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. doi: 10.3390/ijms26125722. PMID: 40565185. (Most recent systematic review; formulation science is the domin… PMID 40565185 | systematic review |
| 2019 | Argireline | Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019 Jun;31(3):263-271. doi: 10.5021/ad.2019.31.3.263.… PMID 33911590 | human trial |
| 2017 | Argireline | Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017 Jun;16(2):271-278. doi: 10.1111/jocd.12314. PMID: 28150423. (Four-ar… PMID 28150423 | human trial |
| 2013 | Argireline | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi: 10.1007/s40257-013-0009-9. PMID: 23417317. (The largest ran… PMID 23417317 | human trial |
| 2013 | Argireline | Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013 Mar;20(3):515-518. doi: 10.1111/ene.12009. PMID: 23146065. (NIH / NIN… PMID 23146065 | human trial |
| 2002 | Argireline | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi: 10.1046/j.1467-2494.2002.00153.x. PMID: 184985… PMID 18498523 | human pilot |
| 2013 | Argireline | Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013 Aug;15(4):237-241. doi: 10.3109/14764172.2013.769273. PMID: 23607739. (Companion murine / clinical paper — D-galactose-aged… PMID 23607739 | preclinical, in vivo |
| 2015 | Argireline | Kraeling MEK, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi: 10.3109/15569527.2014.894521. PMID: 24754410. (Independent FDA in vitro penetration study — ~0.22% of 10% appl… PMID 24754410 | preclinical, in vitro |
| 2021 | Argireline | Lim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PCL, Kang L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J Control Release. 2021 Jan 10;329:907-918. doi: 10.1016/j.jconrel.2020.10.021. PMID… PMID 33068646 | pharmacology |
| 2020 | Argireline | Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 26;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195060. (Contextual review of cosmetic-peptide biochemistry and categorisation;… PMID 33195060 | review |
| 2024 | Argireline | Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. doi: 10.2196/54217. PMID: 38376906. (Google Trends analysis 2013-2023; post-2022 TikTok-driven consumer search surge; coining of "Botox in a bottle" in popular culture.) PMID 38376906 | research article |
| 2020 | Argireline | Lim SH, Tiew WJ, Zhang J, Ho PC, Kachouie NN, Kang L. Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptide. Biofabrication. 2020;12(3):035003. doi: 10.1088/1758-5090/ab6d37. PMID: 31952064. (3D-printed personalis… PMID 31952064 | research article |
| 2013 | Pentapeptide-18 | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23435580. (Placebo-controll… PMID 23435580 | human trial |
| 2014 | Pentapeptide-18 | Dragomirescu AO, Andoni M, Ionescu D, Andrei F. The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide. Cosmetics. 2014;1(2):75-81. doi:10.3390/cosmetics1020075. (Only peer-reviewed open-label human efficacy paper specific to Pentapeptide-18; manufacturer-adjacent but metho… | human pilot |
| 1999 | Pentapeptide-18 | Acosta CG, López HS. delta opioid receptor modulation of several voltage-dependent Ca(2+) currents in rat sensory neurons. J Neurosci. 1999 Oct 1;19(19):8337-8348. doi:10.1523/JNEUROSCI.19-19-08337.1999. PMID: 10493736; PMCID: PMC6783030. (Direct electrophysiological evidence th… PMID 10493736 | preclinical, in vivo |
| 2015 | Pentapeptide-18 | Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi:10.3109/15569527.2014.894521. PMID: 24641245. (Permeation analog study — demonstrates that ~0.22% of topically a… PMID 24641245 | preclinical, in vitro |
| 1975 | Pentapeptide-18 | Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975 Dec 18;258(5536):577-580. doi:10.1038/258577a0. PMID: 1207728. (The landmark Hughes & Kosterlitz p… PMID 1207728 | mechanism / discovery |
| 1977 | Pentapeptide-18 | Hughes J, Kosterlitz HW, Smith TW. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol. 1977 Dec;61(4):639-647. doi:10.1111/j.1476-5381.1977.tb07557.x. PMID: 597668. (Follow-up Hughes/Kosterlitz distribution paper… PMID 597668 | pharmacology |
| 2024 | Pentapeptide-18 | Cullen JM, Cascella M. Physiology, Enkephalin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32491696. (Comprehensive physiology review of enkephalin structure, receptor pharmacology, and degradation — useful pharmacology reference for the Leuph… PMID 32491696 | review |
| 2022 | Pentapeptide-18 | Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022 Apr;44(2):232-248. doi:10.1111/ics.12770. PMID: 35152433. (Independent review of the skin-permeation bottleneck that constrains all topical anti-wrinkl… PMID 35152433 | review |
| 2012 | Pentapeptide-18 | Reddy B, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012 Aug;21(8):569-575. doi:10.1111/j.1600-0625.2012.01528.x. PMID: 22775991. (Dermatology-journal review of bioactive cosmetic oligopeptides including the neurotransmitter-affecting peptid… PMID 22775991 | review |
| 2009 | Pentapeptide-18 | Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009 Sep-Oct;27(5):485-494. doi:10.1016/j.clindermatol.2009.05.013. PMID: 19695481. (Foundational dermatology-journal review of cosmeceutical peptides that contextualizes Leuphasyl within the neurotransmitter-affecti… PMID 19695481 | review |
| 2005 | Pentapeptide-18 | Lipotec S.A. LEUPHASYL®: A New Pentapeptide for Expression Wrinkles. Technical dossier / formulator brochure. Barcelona: Lipotec; 2005. (Originator manufacturer dossier, widely re-cited across cosmetic industry literature; source of the 11.64% stand-alone and 24.62% Leuphasyl +… | industry documentation |
| 2021 | Pentapeptide-18 | Ledwoń P, Errante F, Papini AM, Rovero P, Latajka R. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry. Chem Biodivers. 2021 Feb;18(2):e2000833. doi:10.1002/cbdv.202000833. PMID: 33348441. (Cosmeceutical-peptide review with specific Pentapeptide-18 discussio… PMID 33348441 | research article |
Related pair pages
More research context
Frequently asked
Have Argireline and Pentapeptide-18 been studied together?
Researchers have published mechanistic-level co-administration discussion of Argireline and Pentapeptide-18. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Argireline and Pentapeptide-18 share?
Argireline and Pentapeptide-18 share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Argireline and Pentapeptide-18?
Argireline: Cosmetic ingredient (not a drug). Pentapeptide-18: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Argireline and Pentapeptide-18?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Argireline profile and the Pentapeptide-18 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026